Institution
Gomel State Medical University
Education•Homyel, Belarus•
About: Gomel State Medical University is a education organization based out in Homyel, Belarus. It is known for research contribution in the topics: Medicine & Chemistry. The organization has 586 authors who have published 408 publications receiving 2410 citations.
Topics: Medicine, Chemistry, Internal medicine, Cirrhosis, Population
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This entry is aimed to review the recent AFM applications for the study of dynamics and mechanical properties of intact cells associated with different cell events such as locomotion, differentiation and aging, physiological activation and electromotility, as well as cell pathology.
742 citations
••
German Cancer Research Center1, University of Barcelona2, National University of Colombia3, Manchester Royal Infirmary4, Charles University in Prague5, University of Ljubljana6, Universidad Nacional de Asunción7, University of Birmingham8, Université de Montréal9, Pompeu Fabra University10, Mexican Social Security Institute11, Catholic University of Korea12, University of Lagos13, Bangabandhu Sheikh Mujib Medical University14, Hospital General de México15, NewYork–Presbyterian Hospital16, Gomel State Medical University17, Instituto Português de Oncologia Francisco Gentil18, University of the Philippines19, Koç University20, Hacettepe University21, Indian Council of Medical Research22, University of Hawaii23, Cedars-Sinai Medical Center24, Hospital General San Juan de Dios25, Universidad Nacional Autónoma de Honduras26, Bayero University Kano27, Central University of Venezuela28, University of Chile29, Instituto Potosino de Investigación Científica y Tecnológica30
TL;DR: This large international study to estimate fractions of head and neck cancers attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation confirms the important role ofHPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.
Abstract: BACKGROUND:
We conducted a large international study to estimate fractions of head and neck cancers (HNCs) attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation.
METHODS:
Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity (OC), pharynx, and larynx were collected from pathology archives in 29 countries. All samples were subject to histopathological evaluation, DNA quality control, and HPV-DNA detection. Samples containing HPV-DNA were further subject to HPV E6*I mRNA detection and to p16(INK4a), pRb, p53, and Cyclin D1 immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV E6*I mRNA, and/or p16(INK4a) results.
RESULTS:
A total of 3680 samples yielded valid results: 1374 pharyngeal, 1264 OC, and 1042 laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I mRNA or p16(INK4a), were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three markers. HPV16 was largely the most common type. Estimates of HPV-AF in the oropharynx were highest in South America, Central and Eastern Europe, and Northern Europe, and lowest in Southern Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in Europe and for the larynx in Central-South America.
CONCLUSIONS:
HPV contribution to HNCs is substantial but highly heterogeneous by cancer site, region, and sex. This study, the largest exploring HPV attribution in HNCs, confirms the important role of HPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.
548 citations
••
University of Barcelona1, Middlemore Hospital2, Medical University of Vienna3, Charles University in Prague4, Westmead Hospital5, Instituto Português de Oncologia Francisco Gentil6, Hacettepe University7, American University of Beirut8, Medical University of Lublin9, Manchester Royal Infirmary10, French Institute of Health and Medical Research11, University of Düsseldorf12, Universidad Nacional de Asunción13, Hospital General San Juan de Dios14, Mexican Social Security Institute15, Hospital Italiano de Buenos Aires16, All India Institute of Medical Sciences17, Aristotle University of Thessaloniki18, University of Iowa19, University of Hawaii20, Gomel State Medical University21, Jagiellonian University Medical College22, University of Chile23, Western Galilee Hospital24, Universidad Nacional Autónoma de Honduras25, National Cheng Kung University26, Lagos University Teaching Hospital27
TL;DR: Combined data from HPV-DNA and p16(INK4a) testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV, indicating that HPV contribution in invasive vulvar cancer has probably been overestimated.
320 citations
••
TL;DR: Extensively-drug-resistant ST235 P aeruginosa has rapidly spread throughout Russia and into Belarus and Kazakhstan via clonal dissemination.
Abstract: Summary Background Multidrug-resistant and extensively-drug-resistant Pseudomonas aeruginosa are increasing therapeutic challenges worldwide. We did a longitudinal epidemiological and clinical study of extensively-drug-resistant P aeruginosa in Belarus, Kazakhstan, and Russia. Methods The study was done in three prospectively defined phases: Jan 1, 2002–Dec 31, 2004; Jan 1, 2006–Dec 31, 2007; and Jan 1, 2008–Dec 31, 2010. The first two phases were in Russia only. All consecutive, non-duplicate, nosocomial isolates and case report forms were sent to the coordinating centre (Institute of Antimicrobial Chemotherapy, Smolensk, Russia), where species reidentification, susceptibility testing, and molecular typing of isolates were done. We did susceptibility testing by agar dilution. The presence of metallo-β-lactamase (MBL) genes was established by PCR and sequencing, and class 1 integrons containing MBL gene cassettes were analysed by the PCR restriction fragment length polymorphism approach. Strain relatedness was analysed by multiple loci variable-number tandem-repeat (VNTR) analysis (at six VNTR loci) and multilocus sequence typing. Results In 2002–04, 628 of 1053 P aeruginosa isolates were insusceptible to carbapenems and 47 (4·5%) possessed MBLs. In 2006–07, 584 of 787 isolates were insusceptible to carbapenems and 160 (20·3%) possessed MBLs. In 2008–10, 1238 of 1643 Russian P aeruginosa isolates were insusceptible to carbapenems and 471 (28·7%) possessed MBLs. Additionally, the 32 P aeruginosa isolates from Belarus and Kazakhstan were all carbapenem insusceptible and all possessed MBLs. More than 96% of MBL-positive P aeruginosa isolates were resistant to all antibiotics except colistin (ie, extensively drug resistant), and, in 2010, 5·9% were resistant to colistin. 685 (96·5%) of 710 MBL-positive P aeruginosa belonged to ST235. bla VIM-2 genes were detected in 707 (99·6%) of 710 MBL-positive isolates. Interpretation Extensively-drug-resistant ST235 P aeruginosa has rapidly spread throughout Russia and into Belarus and Kazakhstan via clonal dissemination. Increases in the use of colistin will probably result in further spread of ST235 P aeruginosa resistant to all drugs. Funding HEFC, Ministry of Health of the Russian Federation, Government of the Republic of Belarus, Government of the Republic of Kazakhstan, European Union, Medical Research Council UK–Canada partnership.
164 citations
••
Catholic University of the Sacred Heart1, Agostino Gemelli University Polyclinic2, University of Cologne3, University of Milan4, Medical University of Graz5, University of California, San Diego6, University of Cambridge7, University of Insubria8, University of Milano-Bicocca9, Ankara University10, Masaryk University11, Churchill Hospital12, Autonomous University of Barcelona13, University Medical Center Groningen14, Palacký University, Olomouc15, Hamad Medical Corporation16, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico17, King's College London18, University of Rijeka19, Hospital General Universitario Gregorio Marañón20, Gomel State Medical University21, University of Szeged22, Mansoura University23, Marmara University24, Katholieke Universiteit Leuven25, Karolinska University Hospital26, University of Rome Tor Vergata27, Vanderbilt University Medical Center28, Hospital Universitario La Paz29, University of Belgrade30, Sultan Qaboos University31, Spanish National Research Council32, Wrocław Medical University33, University of Hamburg34, University Hospital of Basel35, Innsbruck Medical University36, Paris-Sorbonne University37, University of Montpellier38, Federal University of Rio de Janeiro39, University Hospital Centre Zagreb40, University of Zagreb41
TL;DR: In this paper, the authors studied the risk factors for adverse outcomes in patients with hematological malignancies (HM) who developed COVID-19 and analyzed predictors of mortality.
Abstract: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
141 citations
Authors
Showing all 589 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ashrafun Nessa | 13 | 26 | 2753 |
Viktoryia Kazlouskaya | 12 | 71 | 471 |
Alessandro Bidossi | 9 | 22 | 653 |
Viktar Mitsura | 7 | 12 | 136 |
Maria N. Starodubtseva | 7 | 16 | 858 |
Dmitry Aleksandrovich Zinovkin | 6 | 14 | 69 |
V. V. Potenko | 5 | 5 | 72 |
Alexander Kozlovsky | 4 | 7 | 46 |
Tatyana G. Kuznetsova | 4 | 4 | 745 |
Christian Andres | 4 | 10 | 166 |
Yu. M. Chernyakova | 3 | 7 | 30 |
I. E. Starodubtsev | 3 | 5 | 15 |
Victor M. Mitsura | 3 | 4 | 57 |
V.A. Yarmolenko | 3 | 6 | 20 |
Oleg Eismont | 3 | 8 | 34 |